- Home
- QNTM vs BTC-USD Comparison
QNTM vs BTC-USD Comparison
Compare QNTM & BTC-USD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- BTC-USD
- Stock Information
- Founded
- QNTM 1998
- BTC-USD N/A
- Country
- QNTM Canada
- BTC-USD
- Employees
- QNTM N/A
- BTC-USD N/A
- Industry
- QNTM
- BTC-USD
- Sector
- QNTM
- BTC-USD
- Exchange
- QNTM NYSE
- BTC-USD
- Market Cap
- QNTM 69.3M
- BTC-USD N/A
- IPO Year
- QNTM N/A
- BTC-USD N/A
- Fundamental
- Price
- QNTM $18.56
- BTC-USD $117,837.16
- Analyst Decision
- QNTM
- BTC-USD
- Analyst Count
- QNTM 0
- BTC-USD 0
- Target Price
- QNTM N/A
- BTC-USD N/A
- AVG Volume (30 Days)
- QNTM 408.2K
- BTC-USD N/A
- Earning Date
- QNTM 08-13-2025
- BTC-USD N/A
- Dividend Yield
- QNTM N/A
- BTC-USD N/A
- EPS Growth
- QNTM N/A
- BTC-USD N/A
- EPS
- QNTM N/A
- BTC-USD N/A
- Revenue
- QNTM N/A
- BTC-USD N/A
- Revenue This Year
- QNTM N/A
- BTC-USD N/A
- Revenue Next Year
- QNTM N/A
- BTC-USD N/A
- P/E Ratio
- QNTM N/A
- BTC-USD N/A
- Revenue Growth
- QNTM N/A
- BTC-USD N/A
- 52 Week Low
- QNTM $2.70
- BTC-USD N/A
- 52 Week High
- QNTM $38.25
- BTC-USD N/A
- Technical
- Relative Strength Index (RSI)
- QNTM 50.64
- BTC-USD 73.77
- Support Level
- QNTM $15.88
- BTC-USD $107,499.56
- Resistance Level
- QNTM $24.32
- BTC-USD $109,731.63
- Average True Range (ATR)
- QNTM 3.58
- BTC-USD 2471.07
- MACD
- QNTM -1.07
- BTC-USD 953.00
- Stochastic Oscillator
- QNTM 13.59
- BTC-USD 94.64
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.